ID: MRFR/Pharma/4106-CR | 90 Pages | Published By Rahul Gotadki on February 2018
Over the last two hundred years, acid reflux has been a common lifestyle problem and also experienced a few setbacks in the U.S. Though, the ultimate goal of the gastroesophageal reflux treatment has always remained the same, which is to suppress the symptoms of the GERD patient. GERD affects up to 40% of the U.S. population in their lifetime and is a part of an increasingly significant public health burden. When GERD is not properly managed, it can lead to Barrett's esophagus. The lifetime risk of progression from GERD to Barrett's esophagus is 26.5%. Early diagnosis and treatment of Barrett's esophagus are crucial because it is the primary risk factor for esophageal cancer. The incidence of acid reflux disorder, also known as heartburn, is rapidly increasing worldwide. Various studies state that almost every person experiences acid reflux once in a lifetime. GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives but also extends to the healthcare system and economy.
The major driving factors for growth of the Americas GERD & NERD treatment market are increasing cases of smoking, rising cases of reflux disorder during pregnancy, changing lifestyle, and irregular dietary habits. Moreover, increasing incidence of acid reflux disorder (heartburn), growing geriatric population are likely to fuel the market growth during the forecast period.
The Americas GERD & NERD treatment market is expected to grow at the CAGR of 4.02% during the forecast period 2017-2023
Figure- Americas GERD & NERD treatment market, by End User 2016 (%)
Source: Source: World Health Organisation, Ministry of Health U.S, Department of Pharmaceutical, National Institute on Drug abuse, American Gastroenterological Association, American College of Gastroenterology, Pediatric/Adolescent Gastroesophageal Reflux Associatestinal Society Anxiety and Depression Association of America, and white papers published by various government organizations, MRFR Analysis
Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis
The Americas GERD & NERD treatment market is segmented on the basis of drug class, dosage form, and by the end user.
On the basis of the drug class, the Americas GERD & NERD treatment market is segmented into antacids (acid neutralizers), proton pump inhibitors, H2 receptor blocker, prokinetic agents, antidepressants, calcium channel blockers, and others. Proton pump inhibitors are further segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. H2 receptor blocker is further segmented into ranitidine, famotidine, cimetidine, nizatidine, and others. Prokinetic agents are further segmented into domperidone, metoclopramide, itopride, prucalopride, cisapride, benzamide, mosapride, erythromycin, and others.
Based on the dosage form, Americas GERD & NERD treatment market is segmented into solid and liquid.
On the basis of the end user, Americas GERD & NERD treatment market is segmented into hospitals & clinics, research centers, and others.
The Americas GERD & NERD treatment market is growing at a steady pace. North America contributed the largest share to the GERD & NERD treatment market owing to continuously increasing demand for the medical devices, increasing number of healthcare organization, and the presence of huge patient population. Increasing cases of smoking are projected to fuel in the Americas market. The South American region accounts the least share of the market.
Key Players in the Americas GERD & NERD Treatment Market
Some of the major players in Americas GERD & NERD treatment are: AstraZeneca Plc (U.K), Boston Scientific Corporation (U.S.), Cempra Inc. (U.S.), Eisai Co., Ltd. (Japan), EndoGastric Solutions Inc. (U.S.), EndoStim Inc. (U.S.), GlaxoSmithKline Plc (U.K), Ironwood Pharmaceuticals, Inc. (U.S.), Jeil pharmaceutical Co. Ltd. (South Korea), Johnson & Johnson (U.S.), Mederi Therapeutics Inc. (U.S.), Medigus Ltd. (Israel), Medtronic Inc. (U.S.), Merck & CO., Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceuticals Industries Limited (Israel), Torax Medical (U.S.), Valeant Pharmaceuticals International, Inc. (Canada), Carbon Medical technologies (U.S.), Allegiant health (U.S.), Tya pharmaceuticals (U.S.), and Sanofi (France).
Americas GERD & NERD treatment market is projected to grow at a 4.02% CAGR By 2023
The Americas is expected to dominate the GERD & NERD treatment market.
Rising incidence of reflux disorder and increasing cases of smoking are key factors driving the GERD & NERD treatment market.
Proton pump inhibitors will dominate the GERD & NERD treatment market.
End users of the GERD & NERD treatment market include research centers, hospitals and clinics, and others.